The 'Hospital at home' (HaH) model avoids hospital admission by transferring healthcare and treatment to the patient's home. We aimed to compare the effectiveness and direct healthcare costs of treating elderly patients with decompensated heart failure (HF) using HaH care vs. inpatient hospital care (IHC) in a cardiology unit.
Introduction
Chronic heart failure (HF) remains a major and growing public health problem in industrialized nations. Its high prevalence in the general population and its increasing incidence, related to ageing of the population and to the increasing survival rates of those suffering from chronic diseases such as ischaemic heart disease, have led it to be considered a true epidemic. 1 In a recent demographic study in Spanish people aged over 45 years, 1776 individuals were evaluated for the presence of HF by their primary care physician, with the subsequent confirmation of the diagnosis by a cardiologist. Results showed that the prevalence of HF was estimated to be 7-8%, similar in men and women, and increasing with age up to 16% in those aged over 75. 2 In
Spain, the cost of a hospital stay for patients with HF is 421.25 Euros/day, with an increase of 71% in the number hospital admissions for CHF and 29-59% of re-admissions in the first 6 months after hospitalization.
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Heart failure is associated with high morbidity and mortality and with frequent hospital re-admissions, it is the most common cause of hospitalization in people aged over 65 years. Heart failure consumes more than 2% of the health care budget in many European countries, up to 70% of which is due to the costs related to hospitalization. 4, 5 In Spain, CHF is the most common cause of hospitalization in people over 65 and it is also the cause of 11% of cardiovascular deaths in men and 19% in women. 6 In this setting, the 2008 guidelines of the European Society of Cardiology 5 recommend the implementation of management programmes for patients with HF (Class I, level A), in an attempt to improve medical care while reducing costs. Basically, the two most widely accepted programmes are HF clinics and home-based care programmes. Both start during admission or just after discharge, and rely on the work of specialized nurses. However, the possibility of avoiding hospital admission by transferring hospital care, including physicians, to the patient's home ['hospital at home' (HaH)] has been proposed recently. 7, 8 Health economic perspectives and information about health-related quality of life 9 have been considered, but studies on this type of management of HF are scarce. For this reason and following current recommendations, 10, 11 we designed a study in patients suffering from worsening chronic HF eligible for hospital admission. Patients identified in the emergency department (ED) were randomly assigned to receive care at home (HaH) or as inpatients in a conventional hospital cardiology ward [inpatient hospital care (IHC)]. The aim of the study was to assess the effectiveness of HaH compared with IHC on the combined outcome of mortality, HF re-admission, or other cardiovascular event (stroke, acute coronary syndrome, and coronary revascularization) as well as the evolution of functional status and quality of life during the index episode and after 1 year of follow-up. The second aim was to compare the health expenditure on each type of care during the initial episode and after 1 year.
Methods

Study design and setting
This prospective, randomized study was performed in Txagorritxu University Hospital, Vitoria-Gasteiz, Spain, which has a catchment population of around 250 000 people. Among other departments, the hospital has a HaH unit, which is staffed by six physicians and eight nurses. The study was approved by the hospital's Ethics and Clinical Research Committee and informed written consent was required from all patients.
Patients aged 65 years with a confirmed diagnosis of HF performed at least 12 months prior to the study, who were in New York Heart Association (NYHA) functional class II or III prior to the current acute exacerbation, were eligible to participate in the study. All patients attended the ED due to a deterioration in HF symptoms and were diagnosed with decompensated chronic HF on the basis of: worsened dyspnoea and/or worsened pulmonary or systemic congestion. All inclusion and exclusion criteria are listed in Table 1 .
A monitoring committee approved inclusion of the patients in the study and validated all clinical events.
Study procedure
All included patients sought care at the ED on their own initiative or were referred by primary care physicians. When the ED doctors diagnosed decompensation of CHF and identified the patient as a potential candidate for the study based on the eligibility criteria, the doctor responsible for recruiting patients into the study was called. The study doctor attended the ED whenever she was required, to confirm the diagnosis of CHF decompensation, check inclusion and exclusion criteria, provide information and to ask the patient for consent to participate. Once the patient had signed the informed consent form, they were randomly assigned (1:1) to one of the intervention groups according to an externally generated sequence, which was hidden from the clinicians until the patient had given consent to participate.
Interventions Inpatient hospital care (IHC)
Patients were admitted to the hospital, cardiology ward and were managed by the usual staff of cardiology specialists and nurses, in accordance with guideline recommendations.
Hospital at home (HaH)
Patients allocated to this group had the characteristics of the HaH unit explained to them while they were still in ED. They were also given an information sheet with contact telephone numbers. Within 12 -24 h of the visit to the ED, patients received scheduled and, if necessary, urgent visits to their homes from an internal medicine specialist and a nurse, who were members of the staff of the HaH unit. In case of deterioration occurring outside the working hours of the unit (from 8 am to 9 pm every day of the year), patients and family were instructed to call 112, Emergencies Services, explaining that they were patients under the supervision of the HaH unit. Apart from the nursing and clinical evaluation, samples were taken for laboratory tests and ECGs were performed in patient's home when necessary. Absence of a telephone at home or living more than 10 km from the hospital
Hospital at home care model for CHF Performance of X-ray and echocardiography at hospital was equally as accessible for HaH patients as for in-patients. As a general rule, all patients were visited daily by a specialist nurse. Patients were visited by a physician daily or every other day depending on their clinical condition. Treatment in HaH finished with referral to primary care after recovery or, in case of deterioration or no response to treatment, with transfer to the cardiology ward.
Follow-up
After the initial admission (intervention), patients were followed up by their primary care physician, who was not aware of the study. A physician or a nurse from the study team contacted each patient at months 1, 3, 6, and 12 to record events such as death, new admissions, or visits to the ED, the cardiologist, or the primary care physician. Blood tests, including NT-proBNP, and re-evaluation of functional status and health-related quality of life were performed at month 12.
Data collection
Baseline variables and clinical data from the index episode that caused admission to the ED were recorded, as well as cardiovascular history with special reference to the number of hospital admissions during the previous year. Blood samples for assessment of NT-proBNP (N-terminal pro-brain natriuretic peptide) levels were drawn in all patients at the ED. Comorbidity was estimated using the Charlson index. 12 Functional status and health-related quality of life prior to decompensation were estimated using the Barthel index 13 and the SF-36 questionnaire, 14 respectively. Left ventricular ejection fraction was measured by echocardiography. Heart failure with preserved ejection fraction was considered ejection fraction 45%.
Effectiveness variables
The following were considered effectiveness variables: necessity to transfer the patient from HaH to IHC during the first admission, mortality due to any cause, re-admission due to HF, or another cardiovascular event (stroke, acute coronary syndrome, and coronary revascularization) during 1 year of follow-up. Variations in functional status (Barthel index) and health-related quality of life (SF-36), since first admission up to 12 months later were also studied.
Cost variables
The following costs were collected for the initial admissions, either to HaH or to cardiology: cost of the stay, medication, diagnostic tests (electrocardiography, echocardiography, laboratory tests, and chest X-ray), consumables, and transport. The health resources used during follow-up which were included in the study costings were: visits to HF clinic, primary care physician or ED, as well as re-admissions.
Cost estimation was based on compensation charged by the Basque Health Service-Osakidetza for hospital stays, visits, and diagnostic tests. 15 Expenditure on pharmaceuticals and consumables was calculated using the reference prices from the hospital's pharmacy service and purchasing department, respectively. For re-hospitalizations, in both the HaH and IHC groups, the cost of the admission was estimated assuming the average cost per day incurred during the first admission for each group.
Statistics
In order to detect real differences of 2000E or more between the two groups with respect to the overall costs associated with hospital admission, a sample size of 37 patients per group was estimated, with a power of 80% and type I error of 5%. 
Results
Between May 2006 and March 2007, 80 patients were included in the study. Nine patients (seven allocated to IHC arm and two to HaH) were withdrawn from the study as follows: three withdrew consent, three due to occurrence of extra-cardiac disease that made follow-up impracticable, and three on the recommendation of the monitoring committee). Seventy-one patients completed the study, of these 34 were admitted to cardiology and 37 to HaH. No significant differences were found in baseline characteristics, including comorbidity, functional status, and health-related quality of life ( Table 2) . Clinical outcomes were similar after initial admission and also after 12 months of follow-up; death or re-admission due to HF or another cardiovascular event occurred in 19 patients in IHC and in 20 in HaH (P ¼ 0.88). Changes in functional status and health-related quality of life after the follow-up did not show significant differences. The average cost of initial admission was 4502 + 2153E in IHC and 2541 + 1334E in HaH (P , 0.001). Over the 12 months after intervention, the average expenditure was 4619 + 7679 and 3425 + 4948E (P ¼ 0.83), respectively.
Effectiveness
Results of clinical effectiveness of both models of care are shown in Table 3 . No deaths or transfers from HaH to IHC occurred during initial admission. During the 12 months after the intervention, five patients died, three from the IHC group and two from the HaH group (P ¼ 0.6). During the same period, incidence of the combined outcome of mortality, re-admission because of HF, or another cardiovascular event was similar in both arms: 19 patients in the IHC group and 20 of the HaH patients. Comparison of the incidence of new admissions due exclusively to new CHF decompensations shows no differences either: in the IHC group, 17 patients (50%) generated 29 new admissions to cardiology and 2 to HaH. Fifteen (40%) of the patients initially treated in the HaH group generated 32 new admissions, 25 to cardiology and 7 to HaH. That is, a total of 32 patients (45%) were re-admitted generating 63 admissions (1.9 re-admission per patient). The variation in quality of life (SF36, physical and mental components) and functional evaluation (Barthel index) was similar in both groups.
Costs
The average cost of admission for the episode of HF that initiated inclusion in the study was lower for HaH (2541 + 1334E compared with 4502 + 2153E; P , 0.001) than for IHC ( Table 4) . This reduction was mainly due to the lower average cost of stays, despite the average stay being shorter in IHC. In HaH, the amount spent on investigations and consumables was smaller. The particulars of this lower use of investigations are as follows: fewer electrocardiography (1.3 + 0.6 vs. 3.4 + 2; P , 0.001), fewer echocardiography (0.4 + 0.5 vs. 0.9 + 0.4; P , 0.001), fewer thorax radiography (1.2 + 0.7 vs. 2 + 0.6; P , 0.001), and fewer laboratory test (3.5 + 1.5 vs. 4.9 + 1.9; P , 0.001).
No significant differences were found in the overall cost per patient during follow-up, nor in the cost due to re-admissions, primary care physicians, or ED visits ( Table 5 ).
Discussion
Our study demonstrates that for patients with decompensated chronic HF, the HaH model of healthcare, with physicians and nurses undertaking visits to the patient's home, obtains similar results to IHC in the cardiology unit with respect to clinical events and quality of life at 1 year, while incurring lower overall costs.
Heart failure still has high rates of mortality and morbidity, despite the therapeutic advances made in recent years. Heart failure especially affects older patients, it is associated with a progressive deterioration in quality of life with frequent admissions to hospital. Patients in our study presented a mortality rate of 7% in the first year, with a re-admission rate of 45%, even though the 32 patients re-admitted accounted for 63 rehospitalizations, corresponding to an average of 2 re-admissions per patient. Considering that the mean age of our patients was 80 and that this age group is especially vulnerable to the adverse effects related to staying in hospital, 16 it seems necessary to find alternatives to traditional hospital admission for patients with worsening HF. In fact, several clinical trials have demonstrated a reduction in the rate of re-admissions, 17 -19 and even a reduction in mortality 20 with no increase in costs 5 with a multidisciplinary home-based intervention. Hospital at home care model for CHF These findings have been confirmed in several meta-analyses reviewing different programmes for the management of HF. 21, 22 In general, these programmes are initiated after hospitalization and have a multidisciplinary approach frequently led by HF nurses. However, the latest large clinical trial published, 23 regarded as definitive study on the subject, shows disappointing results on the role of nurses specialized in management of patients with HF. In these HF management programmes, physician consultations either take place over the phone or patients attend the HF clinic, the physicians do not visit the patient's home. In contrast, in our study, physician home visits were performed regularly. A more recent and, in a sense, more innovative healthcare model is to avoid hospital admissions by transferring hospital care to the patient's home. This is the so-called HaH model of which there are several variations. 24 One model consists of a hospital unit with physicians and nurses going to the patient's home to provide the necessary care, including intravenous medication, laboratory tests, etc. This is the model that has been applied in the current study, as our hospital has a HaH unit with more than 15 years of experience. 25 Initial results from this type of care are encouraging. 25 In a recent meta-analysis 8 which included five clinical trials with patients suffering from different non-cardiac diseases, the most striking result was a reduction in mortality rates at 6 months of follow-up, with a non-statistically significant increase in hospital re-admissions and a reduction in costs. We have not found many studies of the HaH model that only include patients suffering from HF. Leff et al. 7 investigated a subgroup of patients with HF, together with patients showing an exacerbation of chronic pulmonary disease or cellulitis. The study found a lower incidence of complications with a reduction in expenditure of 32% during admission. The reduction of costs during the index admission in our study was 44%, related mainly to the lower expenditure on hospital stays. Furthermore, there were also savings in the HaH group due to the lower rate of investigations and use of consumables ( Table 4) . 
Limitations
The total costs of a disease are derived from the sum of direct, indirect, and intangible costs. The latter two, including loss of income and travel costs for relatives, as well as non-quantifiable costs derived from physical and emotional deterioration and care given by relatives and the community, have not been estimated in the present study. The number of patients in our study was small although we included more patients than others, 9 and the patient numbers conformed to the required sample size estimated before the start of the study. On the other hand, our findings are not applicable to all HF patients, but only to those fulfilling the inclusion and exclusion criteria specified for the study. These results should be confirmed in larger prospective trials.
Conclusions
The HaH care model avoids traditional hospital admission for patients with decompensated chronic HF with no significant differences in clinical and functional outcomes at 1 year of follow-up, but with a substantial reduction in direct costs, more than 40% in the index episode. 
